Legend Biotech Corp is a pioneering biopharmaceutical company focused on creating innovative cell therapies for cancer and other serious diseases. With a leading product candidate aimed at treating multiple myeloma, Legend Biotech is at the forefront of developing chimeric antigen receptor (CAR) T-cell therapies. Their research spans a range of cancers, including leukemia, lymphoma, and various solid tumors. Founded in 2014 and headquartered in Somerset, New Jersey, the company collaborates with Janssen Biotech to advance the reach and effectiveness of its groundbreaking treatments.
With all eyes locked on this morning's CPI release and the Strait of Hormuz nearly shut down, Wall Street analysts are already repositioning across hospitality, pharma, and tech before the market even…
Legend Biotech just posted a quarter that flipped a key narrative for LEGN shareholders, but with a CEO transition underway and the stock still down sharply over the past year, the real…
Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural buyer…
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth. Five therapeutic categories are absorbing most strategic capital: radiopharmaceuticals, next-gen GLP-1,…
Pre-Market Stock Futures: The futures are trading higher this morning, following a solid bounce-back rally across the major indices on Wednesday, after the worst day for stocks since October. Stocks were headed…
